L&H - Exploring the ´tides: Medical Miracle for Obesity?

Exploring the ´tides: Medical Miracle for Obesity?

Image
person's feet on scales measuring weight
Topic
Medical
Language
English
Topic
Topic
Online
Topic
Medical
Language
English
Topic
Topic
Online

Objectifs

Drugs developed for the treatment of diabetes such as semaglutide (marketed as Ozempic or Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro or Zepbound) are being used to decrease the weight of obesity risks:

  • Who are the best candidates for this application?
  • What are the risks and side effects?
  • What might the impact to the industry be?

Contenu

The World Obesity Federation estimates 38% of the global population older than five years is classified as overweight or obese. That figure might balloon to as much as 51% by 2035. A serious medical problem itself, obesity is also associated with cardiovascular diseases, hypertension, hepatic steatosis, sleep apnea syndrome, metabolic abnormalities like type 2 diabetes and dyslipidemia, musculoskeletal disorders, and even cancer. Being obese or overweight can also significantly impact a person’s psychosocial health. Drugs initially targeting Type 2 diabetes have been found to be promising weight-loss treatment alternatives.

Profil du participant

This webinar is suitable for all levels of life insurance professionals, including underwriting, claims, and product development. Attendees may earn one ALU continuing education credit.

Image
person's feet on scales measuring weight

Sessions

This virtual event was held on September 25. Replays are available at the links below.

Intervenant

Image
Richard_Braun_L&H_1000x667

Richard Braun, MD (Chief Medical Director, SCOR US L&H)